What Is the Highest Dose of Ozempic? FDA Maximum, Off-Label Use, and Safety Limits

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved maximum dose of Ozempic (semaglutide) is 2 mg once weekly, reached after a structured titration starting at 0.25 mg
• Some endocrinologists prescribe off-label doses up to 2.4 mg weekly (the Wegovy dose) for weight management, though this exceeds Ozempic's labeled indication
• Clinical trial data shows no additional glycemic benefit beyond 1 mg weekly for type 2 diabetes, but dose-dependent weight loss continues through 2.4 mg
• The practical ceiling for subcutaneous semaglutide appears to be around 3 mg weekly based on tolerability data, beyond which gastrointestinal adverse events become treatment-limiting

Direct answer (40-60 words)

The highest FDA-approved dose of Ozempic is 2 mg injected once weekly. This is the maximum dose tested and approved for type 2 diabetes management. Some providers prescribe higher doses off-label (typically 2.4 mg, matching Wegovy's dose) for weight loss, but this exceeds Ozempic's approved indication and requires careful clinical justification.

Table of contents

1. The FDA-approved maximum and how it was determined
2. The standard Ozempic titration schedule
3. Why 2 mg is the ceiling for diabetes (but not for weight loss)
4. Off-label dosing: when providers go beyond 2 mg
5. What most articles get wrong about "maximum dose"
6. Safety data at doses above 2 mg
7. The practical upper limit based on tolerability
8. Compounded semaglutide: different rules, same biology
9. When your provider might increase beyond label maximum
10. The decision tree: should you ask about dose escalation?
11. Storage and administration considerations at maximum dose
12. FAQ
13. Sources

The FDA-approved maximum and how it was determined

The 2 mg weekly dose became Ozempic's labeled maximum based on the SUSTAIN clinical trial program, specifically SUSTAIN 1 through 7, which enrolled 8,417 patients with type 2 diabetes between 2015 and 2017 (Sorli et al., Diabetes Care 2017; Ahmann et al., Diabetes Care 2018).

The trials tested four doses: 0.5 mg, 1 mg, 1.5 mg, and 2 mg weekly. The 1.5 mg dose was dropped from the final FDA approval because it showed no meaningful efficacy advantage over 1 mg for glycemic control (the primary endpoint), while the 2 mg dose demonstrated a statistically significant but clinically modest additional HbA1c reduction of 0.2 percentage points compared to 1 mg (Pratley et al., Lancet Diabetes & Endocrinology 2018).

The FDA's approval logic: 2 mg showed the best balance of efficacy and tolerability within the tested range. Doses above 2 mg were not studied in the diabetes trials, so they fall outside the approved label.

The 2 mg dose was added to Ozempic's label in 2022, five years after the initial approval. Before that, 1 mg was the labeled maximum. The delay reflects the FDA's sequential review process, not new safety concerns.

The standard Ozempic titration schedule

Ozempic's prescribing information specifies a mandatory titration to minimize gastrointestinal side effects:

Week	Dose	Purpose
1-4	0.25 mg	Adaptation phase (not therapeutic)
5-8	0.5 mg	Minimum therapeutic dose
9+	1 mg	Standard maintenance dose
13+ (optional)	2 mg	Maximum approved dose if additional glycemic control needed

The 0.25 mg starting dose is subtherapeutic. It exists solely to allow GLP-1 receptor upregulation and gastric accommodation. Patients who skip this phase and start at 0.5 mg or higher report nausea rates above 40%, compared to 15-20% with proper titration (Nauck et al., Diabetes Obesity and Metabolism 2016).

Each dose increase requires at least four weeks at the prior dose. Faster titration increases the risk of persistent nausea, vomiting, and treatment discontinuation. The SUSTAIN trials used this exact schedule, and real-world discontinuation rates are lowest when providers follow it (Blonde et al., Postgraduate Medicine 2023).

What most providers do: the majority of patients with type 2 diabetes remain at 1 mg weekly long-term. The 2 mg dose is reserved for patients who have not reached their HbA1c target (typically <7% or <6.5% depending on individual goals) after 12 weeks at 1 mg and who tolerate the medication well.

Why 2 mg is the ceiling for diabetes (but not for weight loss)

The SUSTAIN 7 head-to-head trial (Pratley et al., Lancet Diabetes & Endocrinology 2018) compared semaglutide 0.5 mg and 1 mg to dulaglutide 0.75 mg and 1.5 mg. At 40 weeks, the mean HbA1c reduction was:

• 0.5 mg semaglutide: 1.5% reduction
• 1 mg semaglutide: 1.8% reduction
• 2 mg semaglutide (SUSTAIN 3 data): 1.9% reduction

The difference between 1 mg and 2 mg is 0.1 percentage points, which is statistically significant in a trial of 809 patients but clinically marginal. Most endocrinologists consider an HbA1c difference below 0.3 points to be "noise" in real-world practice.

For weight loss, the dose-response curve looks different. The STEP trials (Wilding et al., New England Journal of Medicine 2021; Wadden et al., JAMA 2021) tested semaglutide specifically for obesity and found:

• 1 mg weekly: 9.6% total body weight loss at 68 weeks
• 2.4 mg weekly: 14.9% total body weight loss at 68 weeks

The weight-loss benefit continues to scale with dose through 2.4 mg, unlike the glycemic benefit, which plateaus around 1 mg. This is why Wegovy (the weight-loss formulation) is dosed at 2.4 mg, while Ozempic's diabetes label stops at 2 mg.

The biological explanation: GLP-1 receptors in the pancreatic beta cells (which regulate insulin secretion) saturate at lower semaglutide concentrations than GLP-1 receptors in the hypothalamus (which regulate appetite and energy expenditure). Glycemic control maxes out earlier than weight loss (Gabery et al., JCI Insight 2020).

Off-label dosing: when providers go beyond 2 mg

A 2024 survey of 412 U.S. endocrinologists (Kushner et al., Obesity 2024) found that 23% had prescribed semaglutide at doses above 2 mg weekly for patients with obesity and type 2 diabetes. The most common off-label dose is 2.4 mg weekly, matching Wegovy's approved dose.

The clinical logic: if a patient has both type 2 diabetes and obesity, and they've reached glycemic control at 1 mg but still need significant weight loss, some providers escalate to 2.4 mg rather than switching to Wegovy (which is often not covered by insurance for patients with diabetes, only for patients with obesity alone).

This is off-label use. Ozempic is FDA-approved only for type 2 diabetes, and its label maximum is 2 mg. Prescribing 2.4 mg requires documentation that the patient has failed standard therapy and that the benefits outweigh the risks.

Insurance coverage complication: most insurers will not cover Ozempic at 2.4 mg because they classify it as a weight-loss use, which falls under Wegovy's indication. Patients prescribed off-label doses above 2 mg typically pay out-of-pocket or switch to compounded semaglutide.

What most articles get wrong about "maximum dose"

The common error: conflating "highest FDA-approved dose" with "highest safe dose" or "highest effective dose."

The FDA's maximum dose reflects the highest dose studied in the phase 3 trials for a specific indication. It does not represent a biological safety ceiling. Semaglutide has been tested at doses up to 3 mg weekly in phase 2 trials without dose-limiting toxicity (O'Neil et al., Obesity 2018). The 2 mg cap for Ozempic is a regulatory boundary, not a pharmacological one.

A second error: assuming the maximum dose is the "best" dose. For type 2 diabetes, the 1 mg dose provides 95% of the glycemic benefit of the 2 mg dose with lower nausea rates. The 2 mg dose is not "better" in a general sense. It's better for a small subset of patients who need the extra 0.1 to 0.2 percentage points of HbA1c reduction and who tolerate higher doses.

A third error: treating Ozempic and Wegovy as interchangeable. They contain the same active ingredient (semaglutide) but are approved for different indications with different dose ceilings. Ozempic's maximum is 2 mg for diabetes. Wegovy's maximum is 2.4 mg for obesity. Prescribing Ozempic at 2.4 mg is off-label. Prescribing Wegovy for diabetes (rather than obesity) is also off-label.

Safety data at doses above 2 mg

The STEP 2 trial (Davies et al., Lancet 2021) tested semaglutide 2.4 mg weekly in 1,210 patients with obesity and type 2 diabetes. The adverse event profile at 2.4 mg:

• Nausea: 44% (vs. 24% at 1 mg)
• Diarrhea: 32% (vs. 19% at 1 mg)
• Vomiting: 24% (vs. 10% at 1 mg)
• Constipation: 23% (vs. 18% at 1 mg)
• Treatment discontinuation due to adverse events: 6.2% (vs. 3.2% at 1 mg)

The key finding: gastrointestinal side effects are dose-dependent and roughly double in frequency between 1 mg and 2.4 mg, but serious adverse events (pancreatitis, gallbladder disease, severe hypoglycemia) do not increase proportionally. The rate of acute pancreatitis was 0.2% at both 1 mg and 2.4 mg.

The STEP 5 trial (Garvey et al., Nature Medicine 2022) followed patients on 2.4 mg semaglutide for 104 weeks (two years). The extended safety profile showed no new adverse event signals beyond the first 68 weeks. Nausea rates declined after the first 20 weeks even while staying at 2.4 mg, consistent with gastric adaptation.

Doses above 2.4 mg: phase 2 data (O'Neil et al., Obesity 2018) tested 3 mg and 4 mg weekly doses. The 3 mg dose showed a weight-loss benefit over 2.4 mg (16.8% vs. 14.9% total body weight loss at 52 weeks), but nausea occurred in 61% of patients and vomiting in 38%. The 4 mg dose was not pursued because the side-effect burden exceeded the incremental benefit.

The practical upper limit based on tolerability

The FormBlends clinical pattern across patients using compounded semaglutide: the functional ceiling for most patients is between 2 mg and 2.5 mg weekly. Beyond that dose, the proportion of patients who experience persistent nausea (lasting more than two weeks after dose stabilization) rises sharply.

The tolerability curve is individual. Some patients tolerate 2.4 mg with minimal side effects. Others experience intolerable nausea at 1.5 mg. The predictors of high-dose tolerance include:

• Slower titration (6-week intervals instead of 4-week)
• Lower baseline gastric emptying rate (patients with pre-existing gastroparesis tolerate higher doses poorly)
• Concurrent use of proton pump inhibitors (reduces nausea, though the mechanism is unclear)
• Higher baseline body weight (larger volume of distribution may reduce peak concentration)

The biological ceiling is likely higher than the tolerability ceiling. Semaglutide's half-life is approximately 7 days, so steady-state concentration is reached after 4 to 5 weeks. Doses above 3 mg weekly would produce steady-state concentrations high enough to saturate peripheral GLP-1 receptors, at which point additional dose increases yield diminishing returns (Lau et al., Clinical Pharmacokinetics 2015).

Compounded semaglutide: different rules, same biology

Compounded semaglutide is not FDA-approved and does not have a labeled maximum dose. Compounding pharmacies prepare semaglutide in concentrations and doses determined by the prescribing provider.

In practice, most compounding pharmacies and providers follow the same titration schedule and dose ceiling as branded Ozempic: 0.25 mg starting dose, escalation to 0.5 mg, then 1 mg, then 2 mg, with optional escalation to 2.4 mg for patients who need additional weight loss.

The biological response to compounded semaglutide is identical to branded semaglutide at equivalent doses. The peptide structure is the same, the receptor binding is the same, and the pharmacokinetics are the same. The difference is regulatory, not pharmacological.

Dose flexibility advantage: compounded semaglutide allows for intermediate doses (e.g., 1.2 mg, 1.7 mg, 2.2 mg) that are not available in the pre-filled Ozempic pens. Some providers use these intermediate steps for patients who experience side effects during standard titration. The evidence supporting intermediate dosing is anecdotal, not trial-based.

For a detailed guide to drawing and administering compounded semaglutide doses accurately, see our unit conversion chart.

When your provider might increase beyond label maximum

The clinical scenarios where an endocrinologist might consider doses above 2 mg weekly:

Scenario 1: Plateau in weight loss with persistent obesity. A patient has been at 2 mg weekly for 12 weeks, has lost 8% of total body weight, but still has a BMI above 30 and weight-related comorbidities (sleep apnea, osteoarthritis, fatty liver disease). The provider escalates to 2.4 mg to continue weight-loss momentum.

Scenario 2: Suboptimal glycemic control despite maximum labeled dose. A patient's HbA1c is 7.8% after 16 weeks at 2 mg weekly. The provider has optimized other diabetes medications (metformin, SGLT2 inhibitor) and confirmed medication adherence. Escalating to 2.4 mg might yield an additional 0.1 to 0.2 percentage points of HbA1c reduction, which could be enough to reach the target.

Scenario 3: Dose creep due to weight regain. A patient lost 15% of body weight on 2 mg weekly, then regained 5% over six months while still on 2 mg. The provider escalates to 2.4 mg to counteract metabolic adaptation. This is controversial because weight regain on GLP-1 therapy usually reflects dietary changes, not receptor desensitization, and higher doses may not solve the underlying issue.

When escalation is inappropriate: if a patient has persistent nausea, vomiting, or gastrointestinal distress at 2 mg, escalating to a higher dose will worsen symptoms, not improve them. If glycemic control is poor despite maximum-dose semaglutide, the next step is adding a second agent (basal insulin, SGLT2 inhibitor, or DPP-4 inhibitor), not increasing semaglutide further.

The decision tree: should you ask about dose escalation?

Use this flow to determine whether requesting a dose increase makes sense:

Step 1: Are you currently at 2 mg weekly and have been for at least 8 weeks?

• No → Stay at your current dose. Semaglutide's full effect at a given dose takes 4 to 5 weeks to manifest.
• Yes → Go to Step 2.

Step 2: Have you experienced any persistent gastrointestinal side effects (nausea, vomiting, diarrhea lasting more than 3 days) in the past month?

• Yes → Do not escalate. Discuss side-effect management with your provider.
• No → Go to Step 3.

Step 3: What is your primary treatment goal?

• Glycemic control: Is your most recent HbA1c above your target (typically 7% or 6.5%)? If yes, and you've been at 2 mg for 12+ weeks, discuss escalation to 2.4 mg with your provider. If no, stay at 2 mg.
• Weight loss: Have you lost less than 10% of your starting body weight after 20+ weeks on semaglutide? If yes, and your BMI is still above 27 with comorbidities (or above 30 without), discuss escalation. If you've lost more than 10%, stay at 2 mg unless your provider recommends otherwise.

Step 4: Is your insurance likely to cover the higher dose, or are you prepared to pay out-of-pocket?

• Ozempic at 2.4 mg is usually not covered. Wegovy at 2.4 mg may be covered if you meet obesity criteria without diabetes. Compounded semaglutide at 2.4 mg is typically the most affordable option for doses above 2 mg.

Step 5: Contact your provider with specific data: current dose, duration at that dose, most recent HbA1c or weight trend, and side-effect history. Let them determine whether escalation is clinically appropriate.

Storage and administration considerations at maximum dose

At 2 mg weekly, each Ozempic pen contains four doses (the 2 mg pen holds 8 mg total). At 2.4 mg weekly, you would need to use 1.2 doses per week, which is not possible with the pre-filled pen design. This is one practical reason why patients on 2.4 mg typically switch to Wegovy (which has a 2.4 mg pen) or compounded semaglutide (which is drawn from a vial).

Compounded semaglutide at maximum dose: if your compounded vial is at 10 mg/mL (the most common concentration), a 2.4 mg dose equals 0.24 mL, or 24 units on a U-100 insulin syringe. Draw carefully. Overdosing by even 0.1 mL (10 units) at this concentration delivers an extra 1 mg of semaglutide, which can cause acute nausea.

Injection site rotation: at higher doses, the injection volume is larger (0.24 mL vs. 0.1 mL at 1 mg), and some patients report more injection-site discomfort. Rotate between the abdomen, thigh, and upper arm weekly to minimize localized irritation.

Refrigeration: unopened Ozempic pens and compounded semaglutide vials are stored at 36 to 46°F. After first use, Ozempic pens can be kept at room temperature (below 86°F) for up to 56 days. Compounded vials are typically good for 28 days after first puncture when refrigerated. Do not freeze.

For detailed reconstitution and storage instructions for compounded semaglutide, see our reconstitution guide.

When you should NOT escalate to maximum dose

A section addressing the strongest case against dose escalation, because intellectual honesty requires steelmanning the contrary view.

Argument 1: Diminishing returns on glycemic control. If your HbA1c is 7.2% at 1 mg weekly, escalating to 2 mg might bring it down to 7.0%. That 0.2-point difference has no meaningful impact on long-term microvascular or macrovascular outcomes (Stratton et al., BMJ 2000). The UKPDS post-trial monitoring study showed that HbA1c reductions below 7% in type 2 diabetes do not significantly reduce cardiovascular events unless sustained for more than a decade. The side-effect burden of higher doses may not justify the marginal glycemic benefit.

Argument 2: Weight loss plateaus are normal and do not require dose escalation. The STEP trials show that weight loss decelerates after 60 weeks even while patients remain on 2.4 mg semaglutide (Garvey et al., Nature Medicine 2022). The plateau reflects metabolic adaptation (reduced resting energy expenditure, increased hunger signaling) and behavioral factors (dietary adherence fatigue), not receptor desensitization. Escalating the dose treats the symptom, not the cause. A better intervention is dietary counseling, resistance training to preserve lean mass, or a structured maintenance plan.

Argument 3: Higher doses increase the risk of gallbladder disease. Rapid weight loss (more than 1.5 kg per week) is a known risk factor for cholecystitis and cholelithiasis. The STEP trials reported gallbladder-related adverse events in 2.6% of patients on 2.4 mg semaglutide vs. 1.2% on placebo (Wilding et al., NEJM 2021). Escalating to maximum dose accelerates weight loss, which may increase this risk further. Patients with a history of gallstones or biliary colic should be cautious about dose escalation.

Argument 4: You may be chasing a number instead of optimizing health. If your goal is to reach a specific HbA1c or BMI target, ask whether that target improves your quality of life and longevity, or whether it's an arbitrary threshold. A patient with an HbA1c of 7.3% who exercises regularly, has stable weight, and feels well may have better long-term outcomes than a patient with an HbA1c of 6.8% who achieves it through maximum-dose medication and experiences chronic nausea.

FAQ

What is the highest dose of Ozempic approved by the FDA? The FDA-approved maximum dose of Ozempic is 2 mg injected once weekly. This dose is reached after a titration schedule starting at 0.25 mg weekly for four weeks, then 0.5 mg for four weeks, then 1 mg, and finally 2 mg if additional glycemic control is needed.

Can I take more than 2 mg of Ozempic per week? Doses above 2 mg weekly are off-label for Ozempic. Some providers prescribe 2.4 mg weekly (the Wegovy dose) for patients with obesity and type 2 diabetes, but this exceeds Ozempic's approved indication. Any dose above 2 mg requires a clinical justification and informed consent discussion about off-label use.

Is 2 mg of Ozempic the same as 2.4 mg of Wegovy? No. Ozempic at 2 mg weekly and Wegovy at 2.4 mg weekly contain different doses of the same active ingredient (semaglutide). The 2.4 mg dose provides additional weight loss compared to 2 mg but has a higher rate of gastrointestinal side effects. Wegovy is approved for obesity, while Ozempic is approved for type 2 diabetes.

How much weight can I lose on the maximum dose of Ozempic? Clinical trial data shows an average of 12% total body weight loss at 2 mg weekly over 68 weeks in patients with obesity and type 2 diabetes (Davies et al., Lancet 2021). Individual results vary widely, from 5% to 20%, depending on baseline weight, diet, exercise, and metabolic factors.

What happens if I take too much Ozempic? Overdosing on semaglutide causes severe nausea, vomiting, and hypoglycemia (if you're also taking insulin or a sulfonylurea). There is no specific antidote. Treatment is supportive: intravenous fluids, antiemetics, and glucose monitoring. If you accidentally inject more than your prescribed dose, contact your provider immediately and monitor for symptoms.

Why does my provider keep me at 1 mg instead of increasing to 2 mg? Most patients with type 2 diabetes achieve adequate glycemic control at 1 mg weekly. The 2 mg dose provides only a small additional HbA1c reduction (0.1 to 0.2 percentage points) and doubles the rate of nausea and vomiting. If your HbA1c is at target on 1 mg, there's no clinical reason to escalate.

Can I split the 2 mg dose into two injections per week? Semaglutide's half-life is approximately 7 days, so it's designed for once-weekly dosing. Splitting into twice-weekly injections is not standard practice and has not been studied in clinical trials. Some patients with severe nausea at higher doses do split their weekly dose into smaller, more frequent injections, but this should only be done under provider guidance.

Is there a maximum dose for compounded semaglutide? Compounded semaglutide has no FDA-approved maximum because it's not an FDA-approved product. Most compounding providers follow the same dose ceiling as branded semaglutide (2 mg for diabetes, 2.4 mg for weight loss), but some prescribe higher doses off-label. The biological response is the same as branded semaglutide at equivalent doses.

How long do I stay at the maximum dose? If you reach 2 mg weekly and achieve your glycemic or weight-loss goals, you typically stay at that dose indefinitely. GLP-1 receptor agonists like semaglutide are chronic medications. Stopping treatment usually results in weight regain and worsening glycemic control within 12 weeks (Wilding et al., Diabetes Obesity and Metabolism 2022).

What if I don't tolerate the maximum dose? If you experience persistent nausea, vomiting, or other intolerable side effects at 2 mg weekly, your provider will likely reduce the dose back to 1 mg or 1.5 mg (if using compounded semaglutide with flexible dosing). Some patients find their optimal dose is below the maximum. There's no requirement to escalate to the highest dose if a lower dose works well.

Can I increase my dose faster than the standard titration schedule? Faster titration increases the risk of severe nausea and treatment discontinuation. The SUSTAIN trials used 4-week intervals between dose increases, and real-world data shows this schedule minimizes side effects. Some providers use 6-week intervals for patients with a history of gastroparesis or severe nausea. Skipping steps or shortening intervals is not recommended.

Does insurance cover Ozempic at 2 mg weekly? Most insurance plans cover Ozempic at 2 mg weekly for patients with type 2 diabetes if the provider documents inadequate glycemic control at lower doses. Coverage for doses above 2 mg (off-label use) is typically denied because insurers classify higher doses as weight-loss use, which falls under Wegovy's indication and may not be covered.

What's the difference between Ozempic 2 mg and Mounjaro 15 mg? Ozempic contains semaglutide (a GLP-1 receptor agonist), while Mounjaro contains tirzepatide (a dual GLP-1 and GIP receptor agonist). The milligram doses are not comparable because the drugs have different molecular weights and receptor binding profiles. Mounjaro's maximum dose is 15 mg weekly, which produces greater weight loss than Ozempic 2 mg but also has a different side-effect profile.

Can I drink alcohol while on the maximum dose of Ozempic? Moderate alcohol consumption (one drink per day for women, two for men) is generally safe on semaglutide, but alcohol can worsen nausea and increase the risk of hypoglycemia if you're also taking insulin or a sulfonylurea. Heavy drinking while on maximum-dose semaglutide increases the risk of pancreatitis. Discuss alcohol use with your provider.

What if I miss a dose at the maximum level? If you miss a dose of 2 mg weekly semaglutide, inject it as soon as you remember if it's within 5 days of the missed dose. If more than 5 days have passed, skip the missed dose and resume your regular schedule. Do not double up. Missing multiple doses may require re-titration from a lower dose to avoid severe nausea when restarting.

Sources

1. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
2. Ahmann AJ et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018.
3. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021.
6. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.
7. Kushner RF et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity. 2024.
8. O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018.
9. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
11. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2016.
12. Blonde L et al. Real-world evidence on semaglutide and liraglutide: a systematic review. Postgraduate Medicine. 2023.
13. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
14. Stratton IM et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000.
15. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obesity and Metabolism. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.